ANDA 62692, held by Hikma Pharmaceuticals. Ampicillin Sodium.
As of Nov 21, 2026, ANDA 62692 (Ampicillin Sodium), held by Hikma Pharmaceuticals, was first approved by FDA on Jun 24, 1986, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 24, 1986 | Original application | Approved | None posted |
| Ampicillin SodiumEQ 125MG BASE/VIAL · injectable;injection | Ampicillin Sodium | Discontinued |
| Ampicillin SodiumEQ 250MG BASE/VIAL · injectable;injection | Ampicillin Sodium | Discontinued |
| Ampicillin SodiumEQ 500MG BASE/VIAL · injectable;injection | Ampicillin Sodium | Discontinued |
| Ampicillin SodiumEQ 1GM BASE/VIAL · injectable;injection | Ampicillin Sodium | Discontinued |
| Ampicillin SodiumEQ 2GM BASE/VIAL · injectable;injection | Ampicillin Sodium | Discontinued |
| Ampicillin SodiumEQ 10GM BASE/VIAL · injectable;injection | Ampicillin Sodium | Discontinued |
| May 1, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Aug 16, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jun 24, 1986 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters